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The Nef protein of Human Immunodeficiency Virus (HIV) and Simian Immunodeficiency Virus (SIV) is a pluripotent accessory protein that
plays a critical role in disease progression. One analogous characteristic of Nef proteins from SIV and HIV is the ability to associate with cellular
kinases. We have previously reported that the Nef protein from a macrophage-tropic neurovirulent SIV clone, SIV/17E-Fr, is associated with an
unknown kinase activity that is distinct from the p21-associated kinase that interacts with SIVmac239 Nef. Using site-directed mutagenesis and
kinase-specific inhibitors, we have identified this kinase as the ubiquitous serine/threonine kinase, protein kinase CK2.
© 2006 Elsevier Inc. All rights reserved.Keywords: Nef; SIV; Neurovirulent; Protein kinase CK2Introduction
A functional Nef protein is required in vivo for the
pathogenesis of HIV and SIV; however, identification of the
critical function(s) of Nef required in vivo is still under
investigation. Adult rhesus macaques infected with SIV
containing a deletion in the nef gene do not progress to disease
(Kestler et al., 1991). Furthermore, SIV with a defective nef
gene has been shown to mutate in vivo, restoring Nef functions
that allow for disease progression (Alexander et al., 2003; Carl
et al., 2000; Sawai et al., 2000). In vitro studies have suggested
a number of mechanisms by which Nef can contribute to the
pathogenicity of HIV and SIV including immune evasion, CD4
down-regulation, and increasing virion infectivity (reviewed in
Peter, 1998). More recently, Nef has been shown to play a
significant role in modulating apoptosis. Nef can both protect
infected cells from apoptosis through interactions with Ask-1
and p53 (Geleziunas et al., 2001; Greenway et al., 2002) while
inducing apoptosis in virus-specific cytotoxic T lymphocytes
through induction of FasL (Xu et al., 1999). Less appreciated,
however, is the importance of Nef to neurovirulence (Flaherty et⁎ Corresponding author.
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mechanisms have been proposed to account for this pathogenic
function of Nef (He et al., 1997; Kohleisen et al., 1999;
Robichaud and Poulin, 2000). Moreover, it is not clear how
functions of Nef important for the pathogenesis of AIDS will
translate to the function(s) of Nef in neuropathogenesis,
especially given the immune-privileged status of the central
nervous system (CNS) and the fact that little CD4 is expressed
in the brain (Peudenier et al., 1991).
The SIV/macaque model is the best available model for
studying the neuropathogenesis of HIV. SIV infection of Asian
macaques results in an AIDS-like disease that closely parallels
HIV CNS infection of humans (Anderson et al., 1993; Kestler
et al., 1990; Letvin et al., 1985; Naidu et al., 1988; Sharma et
al., 1992). Previously, we derived a neurovirulent viral swarm,
SIV/17E-Br, from multiple in vivo passages of the prototypic
lymphocyte-tropic virus SIVmac239 in the macaque model
(Sharma et al., 1992). Through generation and characterization
of a panel of recombinant viruses (between SIV/17E-Br and
SIVmac239), we identified SIV/17E-Br env and nef as the
critical determinants of neurovirulence (Flaherty et al., 1997;
Mankowski et al., 1997). These initial studies culminated in
the derivation of a neurovirulent molecular clone, SIV/17E-Fr,
that when inoculated into macaques leads to the development
Fig. 1. CK2 phosphorylates SIV/17E-Fr Nef. (A) Sequence of the 20 amino
acids at the N-terminus of the SIV/17E-Fr Nef protein. The relevant serine 12
and aspartic acid 15 are enlarged. (B) Recombinant CK2 was incubated with
recombinant Nef cleaved from a GST-Nef fusion protein as described in
Materials and Methods. Shown is Nef + CK2, Nef alone, and CK2 alone.
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1997).
The nef gene of HIVand SIV has been shown to accumulate
a number of mutations during infection (Kirchhoff et al., 1999;
Whatmore et al., 1995; Zanotto et al., 1999). The SIV/17E-Fr
Nef protein, in particular, acquired 5 out of 263 possible amino
acid changes, during the in vivo passage of SIVmac239
(Flaherty et al., 1997). To identify differences between the
Nef proteins of the lymphocyte-tropic SIVmac239 and the
macrophage-tropic, neurovirulent SIV/17E-Fr that might relate
to neurovirulence, we constructed another recombinant virus,
SIV/Fr-2. SIV/17E-Fr and SIV/Fr-2 are identical except that
SIV/Fr-2 has the open nef gene from SIVmac239 whereas SIV/
17E-Fr has the open nef gene from the neurovirulent swarm
SIV/17E-Br. Both SIV/17E-Fr and SIV/Fr-2 have similar levels
of Nef incorporation into the virion and Nef-dependent
infectivity (Flaherty et al., 1998). Interestingly, SIV/17E-Fr
Nef but not SIV/Fr-2 Nef is phosphorylated in cells labeled in
cell culture with [32P]-orthophosphate. However, in vitro kinase
assays indicated that SIV/Fr-2 Nef associates with the
previously characterized p21-activated kinase 2 (PAK-2) and
an unidentified serine kinase present in the Nef-associated
kinase complex (NAKC) (Arora et al., 2000; Baur et al., 1997)
in cells but not in virions. To determine which of the mutations
occurring from in vivo passage of SIVmac239 was responsible
for this differential phosphorylation, an additional panel of
recombinant viruses was constructed (Barber et al., 2000). The
SIV/Fr-2 Nef kinase associations were largely dependent on the
presence of a glutamic acid at position 150. SIV/17E-Fr Nef
expresses a lysine at position 150 and does not interact with
either PAK-2 or NAKC in cells or virions, but does associate
with an unidentified kinase in both cells and virions.
Phosphorylation of SIV/17E-Fr Nef by the unidentified kinase
is dependent on the serine at position 12; SIV/Fr-2 Nef has a
proline at position 12 and is not phosphorylated by this kinase.
One of the most versatile and common aspects of the
pluripotent Nef protein is its ability to interact with cellular
signaling pathways. Nef has been shown to modulate the
activities of a number of cellular kinases, including hck (Briggs
et al., 1997; Moarefi et al., 1997), lck (Collette et al., 1996;
Greenway et al., 1996), PKC-θ (Smith et al., 1996), mitogen-
activated protein kinase (MAPK) (Greenway et al., 1996), PAK-
2 (Arora et al., 2000), and NAKC (Baur et al., 1997).
Downstream effects of Nef signaling functions include
modulation of apoptosis, cellular transformation, and induction
of cellular gene transcription (reviewed in Renkema and
Saksela, 2000); however, it is important to note that the balance
of these studies has been carried out in T lymphocytes. Few
studies have addressed the ability of Nef to modulate signaling
pathways in the brain, although two reports studied positive and
negative modulation of apoptosis pathways in astrocytes (He et
al., 1997; Robichaud and Poulin, 2000). To our knowledge, no
study has examined the phosphorylation and kinase association
of a Nef protein derived specifically from a neurovirulent virus.
Identification of a kinase associated with SIV/17E-Fr Nef may
prove invaluable for elucidating functions of Nef important in
CNS-specific cells and in neuropathogenesis. Here, employingsite-directed mutagenesis and newly developed, highly specific
kinase inhibitors, we demonstrate that protein kinase CK2
(CK2) specifically associates with and phosphorylates SIV/
17E-Fr Nef.
Results
CK2 phosphorylates SIV/17E-Fr Nef in vitro
We have previously reported that an unidentified kinase
phosphorylates the SIV/17E-Fr Nef protein. A serine at position
12 in the SIV/17E-Fr Nef protein is required for this specific
phosphorylation event. This serine is found within a consensus
CK2 site that generally consists of the target serine or threonine
and an acidic amino acid, either aspartic acid, glutamic acid, or a
phosphorylated serine/threonine + 3 from the target amino acid
(Meggio et al., 1994) (Fig. 1A). However, factors other than the
consensus site can influence CK2 phosphorylation, such as the
surrounding protein environment, but these conditions are
variable (He et al., 1997; Robichaud and Poulin, 2000).
Negatively charged amino acids in the region increase
phosphorylation but are not necessary. Some proteins, such as
p53, that are phosphorylated by CK2 have nearly unrecogniz-
able consensus sites, but it is thought that the structure of the
protein facilitates CK2 binding (Blaydes and Hupp, 1998;
Wallace et al., 2001). CK2 has also been shown to
phosphorylate the Saccharomyces cerevisiae protein Fpr3 on
a tyrosine that is found in a consensus CK2 site, even though it
is classically known as a serine/threonine kinase (Marin et al.,
1999; Wilson et al., 1995). Together, these findings suggest a
minimal consensus site for CK2 along with a number of factors
that can influence phosphorylation by CK2.
We used a cell-free in vitro system to determine if SIV/17E-
Fr Nef is a potential substrate for CK2. SIV/17E-Fr Nef
expressed in bacteria as a GST fusion protein was cleaved from
GST using Factor Xa (New England Biolabs). Purified Nef was
incubated with recombinant CK2 (Promega) and [32P]-γATP
then resolved by SDS-PAGE as described in Materials and
Methods (Fig. 1B). SIV/17E-Fr Nef is readily phosphorylated
by CK2 while SIV/17E-Fr Nef alone is not phosphorylated in
accordance with literature contesting the ability of Nef to
autophosphorylate (Backer et al., 1991). Because in vitro
phosphorylation alone does not prove that SIV/17E-Fr Nef and
Fig. 2. Mutation of the serine at position 12 correlates with phosphorylation of
SIV/17E-Fr Nef in in vitro kinase assays. Quantitative analysis is of 3
independent in vitro kinase assays using Nef immunoprecipitates from lysates of
293T cells transfected with SIV/17E-Fr DNA containing Nef mutations. SIV/
17E-Fr Δnef is used as a negative control; quantitation from this sample was
subtracted equally from all samples in each experiment. (A) In vitro kinase
assays performed with [32P]-γATP. There was a statistically significant
difference between the phosphorylation of SIV/17E-Fr Nef and the S(12)P
Nef using [32P]-γATP. [ANOVA; P b 0.0001]. (B) In vitro kinase assays
performed with [32P]-γGTP. There was a statistically significant difference
between the phosphorylation of SIV/17E-Fr Nef and the S(12)P Nef [32P]-
γGTP. [ANOVA; P b 0.0001]. (C) Nef immunoprecipitation from [35S]Met/Cys
labeled 293T cell lysate. No statistically significant difference in Nef expression
was observed in 3 independent experiments. [ANOVA; P N 0.05] (data not
shown).
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examine a physiologically relevant interaction between these
two proteins in infected cells.
Site-directed mutagenesis is consistent with phosphorylation by
CK2
Previous studies have suggested that the serine at position 12
in SIV/17E-Fr Nef is important for Nef phosphorylation by an
unidentified kinase (Barber et al., 2000). To confirm the
importance of serine 12 in Nef phosphorylation and to further
characterize the putative CK2 site, we performed a thorough
and quantitative examination of this serine as well as proximal
amino acids. Serine 12 in the SIV/17E-Fr Nef protein was
changed to proline; SIVmac239 Nef, which is not phosphor-
ylated by the kinase, contains a proline at amino acid position
12. Viral clones were transfected into 293T cells and the Nef
proteins from cell lysates were analyzed for phosphorylation by
in vitro kinase assays (Fig. 2A). The presence of proline at
position 12 in the SIV/17E-Fr Nef protein reduces the
phosphorylation of Nef by 70%. Because the kinase responsible
for the SIV/17E-Fr Nef phosphorylation utilizes both ATP and
GTP as phosphodonors, an uncommon characteristic for
kinases, we next examined the phosphorylation of S(12)P Nef
in the presence of GTP and observed a similar pattern of Nef
phosphorylation (Fig. 2B). The Nef mutant was also tested in
CEMx174 cells and the same pattern of phosphorylation was
observed for ATP and GTP indicating that this is not a cell-type-
specific event (data not shown). Both wild type SIV/17E-Fr and
the S(12)P virus exhibit no statistically significant difference in
Nef expression as demonstrated by immunoprecipitation from
cells labeled with [35S]Met/Cys (Fig. 2C). Thus, these results
reflect levels of phosphorylation and confirm the importance of
serine 12 for Nef phosphorylation.
Because the aspartic acid at position 15 is an important
amino acid in the consensus CK2 site, we mutated SIV/17E-Fr
to express the neutral amino acid alanine at this position. The
SIV/17E-Fr D(15)A Nef protein shows a 74% reduction in
phosphorylation in in vitro kinase assays from 293T cell
lysates using radiolabeled ATP (Fig. 3A). Reduced phosphor-
ylation of Nef is also observed when using radiolabeled GTP,
with phosphorylation reduced by 60% (Fig. 3B). Since the
minimal consensus CK2 site can utilize aspartic acid or
glutamic acid, we generated a conservative mutation in the
Nef CK2 site from the native aspartic acid to a glutamic acid.
In vitro kinase assays from 293T cells transfected with SIV/
17E-Fr mutants indicated that the D(15)E mutation maintained
phosphorylation of the Nef protein in the presence of
radiolabeled ATP, albeit to a lesser extent than wild type
Nef (Fig. 3A). In vitro kinase assays using GTP maintain the
phosphorylation at approximately wild type levels with a
conservative mutation in the CK2 consensus site (Fig. 3B).
The same results were also observed in CEMx174 cells (data
not shown). Immunoprecipitation of the different mutant Nef
proteins from cells labeled with [35S]Met/Cys shows that the
protein levels in the kinase assay are statistically not different
between the mutants (Fig. 3C) indicating that these resultsreflect different levels of phosphorylation of Nef and not
different Nef protein levels. Since aspartic acid and glutamic
acid are very similar in size and charge, results from the D(15)
E mutant also suggest that the loss of phosphorylation with the
D(15)A mutant is not a consequence of changing the aspartic
acid. The D(15)E mutation maintains the CK2 consensus site
and therefore supports phosphorylation. Thus, we conclude
that aspartic acid 15 is involved in SIV/17E-Fr Nef
phosphorylation. This result strengthens the hypothesis that
the kinase phosphorylating the SIV/17E-Fr Nef protein is
CK2.
All of these Nef point mutants were tested in labeled cell
culture for possible affects on Nef phosphorylation. 293T cells
were transfected with the viral DNA for each Nef mutant,
Fig. 4. The serine 12 and aspartic acid 15 mutations affect SIV/17E-Fr Nef
phosphorylation in vivo. Nef immunoprecipitates were prepared from cell
lysates made from labeled 293Tcells as described in Materials and Methods. (A)
[32P]-orthophosphate labeled cells. (B) [35S]Met/Cys labeled cells. (C) [32P]-
orthophosphate labeled cells. (D) [35S]Met/Cys labeled cells. In panels B and D,
no statistically significant difference in Nef expression was observed in 3
independent experiments [ANOVA; P N 0.05] (data not shown).
Fig. 3. The amino acid at position 15 in SIV/17E-Fr Nef is important for
phosphorylation. Quantitative analysis is of 3 independent in vitro kinase assays
using Nef immunoprecipitates from lysates of 293T cells transfected with SIV/
17E-Fr DNA containing Nef mutations. SIV/17E-Fr Δnef is used as a negative
control; quantitation from this sample was subtracted equally from all samples in
each experiment. (A) In vitro kinase assay performed with [32P]-γATP. There is
a statistically significant difference in phosphorylation between SIV/17E-Fr Nef
and D(15)A Nef, as well as between D(15)A Nef and D(15)E Nef using [32P]-
γATP. [ANOVA; P b 0.0001]. (B) In vitro kinase assay performed with [32P]-
γGTP. There is a statistically significant difference in phosphorylation between
SIV/17E-Fr Nef and D(15)A Nef, as well as between D(15)A Nef and D(15)E
Nef using [32P]-γGTP. [ANOVA; P b 0.0001]. (C) Nef immunoprecipitation
from [35S]Met/Cys labeled 293T cell lysate. No statistically significant
difference in Nef expression was observed in 3 independent experiments.
[ANOVA; P N 0.05] (data not shown).
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subjected to lysis and immunoprecipitation of the mutant Nef
proteins. The S(12)P Nef mutant produced an identical
phosphorylation pattern to the in vitro kinase assays (Fig.
4A). Also seen in the in vitro kinase assays, the D(15)A Nef
protein has greatly reduced phosphorylation in labeled cell
culture while the D(15)E Nef protein maintains the SIV/17E-Fr-
specific Nef phosphorylation (Fig. 4C). There is no statistically
significant difference in Nef expression, as measured by [35S]
Met/Cys labeled immunoprecipitations (Figs. 4B and D). These
results were also observed in CEMx174 cells (data not shown).
Thus, the S(12)P and D(15)A Nef mutants exhibit decreasedphosphorylation in in vitro kinase assays and during SIV
replication in vivo. Collectively, these data suggest the
existence of a functional CK2 site consisting of a target serine
at position 12 and an important aspartic acid at position 15.
CK2-specific inhibitors reduce SIV/17E-Fr Nef protein
phosphorylation
Since our data strongly suggest that the SIV/17E-Fr Nef
phosphorylation site involves the serine at position 12 and the
aspartic at position 15 (the minimal consensus CK2 site), we
used this information to further explore the identity of the kinase
responsible for Nef phosphorylation. Specific kinase inhibitors
are commonly employed to examine the involvement of a
kinase in a phosphorylation event in in vitro kinase assays and
in labeled cell culture. We utilized two newly developed, highly
specific and potent inhibitors of CK2 to examine the
phosphorylation of the Nef protein.
4,5,6,7-tetrabromobenzotriazole (TBB) is an ATP analogue
that specifically inhibits CK2 and does not affect the activity
of more than 30 other protein kinases tested (Battistutta et al.,
2001; Sarno et al., 2001). TBB is a well characterized
inhibitor routinely used to inhibit phosphorylation of proteins,
in labeled cell culture, that have been shown to be
physiological substrates of CK2 (Kulartz et al., 2004;
Ljubimov et al., 2004; Schwartz et al., 2004). 293T cell
cultures were transfected with SIV/17E-Fr DNA and labeled
with either [32P]-orthophosphate or [35S]Met/Cys in the
presence or absence of TBB the next day. Nef was
immunoprecipitated and phosphorylation was quantified by
phosphorimager (Fig. 5). The percent decrease in phosphor-
ylation was calculated by dividing the intensity of the 32P
band (measuring phosphorylation) by the intensity of the 35S
band (measuring total amount of Nef protein). With 50 μM
TBB, a 49% decrease in Nef phosphorylation was observed
whereas no decrease was observed with the DMSO vehicle
control. Similar levels of phosphorylation inhibition have
been observed for other CK2 substrates with this
Fig. 6. DMAT inhibits SIV/17E-Fr Nef phosphorylation and CK2 α′ autopho-
sphorylation in in vitro kinase assay. (A) Nef immunoprecipitates were prepared
from lysates of CEMx174 cells transfected with SIV/17E-Fr DNA and subjected
to in vitro kinase assay using [32P]-γATP as described in Materials andMethods.
DMAT or DMSO vehicle control (representing the amount of DMSO present in
50 and 200 mM DMAT) was added to the kinase buffer during the kinase assay.
SIV/17E-Fr Δnef is used as a negative control; quantitation from this sample
was subtracted equally from all samples in each experiment. Data were
generated by phosphorimager analysis and are representative of 3 independent
in vitro kinase assays. There is a statistically significant difference between the
DMAT-treated samples and the untreated sample, as well as between the DMAT-
treated samples and the respective vehicle controls [ANOVA; P b 0.001]. Nef
Western blot was performed to monitor protein levels in each immunoprecip-
itate. (B) CK2 α′ was immunoprecipitated from CEMx174 cells and subjected
to in vitro kinase assay using [32P]-γATP as described in Materials andMethods
[ANOVA; P b 0.05]. CK2 α′ Western blot was performed to monitor the levels
of CK2 α′ in each immunoprecipitate.
Fig. 5. TBB inhibits SIV/17E-Fr Nef phosphorylation in vivo. Nef protein
immunoprecipitated from 293T cells labeled with [32P]-orthophosphate or [35S]
Met/Cys and treated with TBB or with a DMSO vehicle control was analyzed by
phosphorimager. SIV/17E-Fr Δnef is used as a negative control; quantitation
from this sample was subtracted equally from all samples in each experiment.
Data are representative of 3 independent experiments. There is a statistically
significant difference in phosphorylation between the untreated sample and the
TBB treated sample, as well as between the TBB treated sample and the vehicle
control [ANOVA; P b 0.001].
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2004). Higher concentrations of TBB did not further reduce
the amount of Nef phosphorylation (data not shown). A 49%
decrease in phosphorylation strongly implicates CK2 in the
phosphorylation of Nef; however, we cannot rule out the
involvement of other kinases involved in Nef phosphorylation
since TBB did not completely inhibit the phosphorylation.
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
(DMAT) is a derivative of TBB designed to be a more potent
inhibitor of CK2 (Pagano et al., 2004a, 2004b). We tested the
affect of DMAT on Nef phosphorylation in an in vitro kinase
assay on Nef protein immunoprecipitated from CEMx174
cells transfected with SIV/17E-Fr DNA. 50 μM DMAT
reduces the phosphorylation of Nef by 43% while 200 μM
DMAT reduces the phosphorylation by 70% as compared to
Nef phosphorylation without DMAT (Fig. 6A). DMAT
reduces Nef phosphorylation by inhibiting the kinase reaction
since Western blot analysis of the in vitro kinase assay shows
similar levels of Nef protein between reactions. DMAT is not
very well characterized in the literature; therefore, we used
the autophosphorylation activity of the CK2 α′ subunit in our
in vitro kinase assay as a measure of DMAT inhibition
(Donella-Deana et al., 2001). We found a similar pattern of
inhibition for both SIV/17E-Fr Nef and CK2 α′ (Fig. 6B).
Thus, Nef phosphorylation was reduced with two different,
highly specific CK2 inhibitors in two different cell types and
two different experimental assays indicating that CK2phosphorylates Nef under physiological conditions in infected
cells.
Discussion
In this report, we have identified CK2 as a kinase that
phosphorylates the Nef protein of a neurovirulent SIV. The
ubiquitously expressed CK2 is one of the most highly
161M.J. Caples et al. / Virology 348 (2006) 156–164conserved kinases in evolution and plays a global role in the
regulation of cellular processes, particularly signal transduction
pathways, gene expression, and cell survival (reviewed in
Litchfield, 2003; Pinna, 2002). In 2003, the number of CK2
substrates was calculated to be 307 (Pinna, 2002); however, that
number has undoubtedly grown. Among the list of the many
substrates for CK2 are a number of HIV proteins. CK2 has been
shown to phosphorylate Reverse Transcriptase (Harada et al.,
1998; Lazaro et al., 2000), gp120, gp41, Capsid (Ohtsuki et al.,
1998), Vpu (Schubert et al., 1994), Protease (Haneda et al.,
2000), and Rev (Meggio et al., 1996, 2001). The present work
demonstrates that the Nef protein derived from a neurovirulent
SIV is also phosphorylated by CK2. It is curious that such a
significant number of HIV/SIV proteins seem to interact with
this multifunctional kinase. However, since it is generally active
in the absence of stimulation or addition of cofactors (Sarno et
al., 2002), CK2 may simply provide an amenable and readily
available kinase for HIVand SIV to co-opt for replication and/or
neuropathogenic purposes. It is not surprising then that SIV/
17E-Fr Nef would interact with CK2, especially in the CNS
where CK2 has been shown to be an important enzyme for
normal function and abnormal pathologies in the brain
(reviewed in Blanquet, 2000).
Nef phosphorylation by CK2 is directly linked to a serine at
amino acid position 12 in the Nef protein from SIV/17E-Fr.
SIV/17E-Fr was derived previously through serial in vivo
passage of the prototypic, lymphocyte-tropic virus SIVmac239
resulting in the neurovirulent virus SIV/17E-Br and subse-
quent molecular clones of the env, nef, and 3′ LTR of SIV/
17E-Br into the SIVmac239 backbone (Sharma et al., 1992).
Sequence analysis of the nef gene from brain homogenates of
a rhesus macaque infected with an uncloned viral swarm of
SIV/17E-Br revealed conversion of the SIVmac239 proline at
position 12 to serine in 9 out of 9 independent PCR reactions
(Barber et al., 2000). This suggests a selective pressure for
conversion of the proline to serine at position 12, a hypothesis
supported by phylogenetic and protein structure analyses
providing evidence for viral evolution toward a neurotropic
HIV Nef protein (van Marle et al., 2004). Intriguingly,
sequence analysis of the nef gene from the brains of macaques
infected with SIV/Fr-2 also revealed conversion of the proline
at position 12 to serine in 2 out of 2 macaques, while the nef
sequences in the peripheral blood and tissue maintained the
wild type proline (unpublished data). As mentioned previous-
ly, SIV/Fr-2 is isogenic to SIV/17E-Fr except with the open
nef gene from SIVmac239, suggesting that a serine at position
12 may be selected for during the natural evolution of viral
sequences in the brain.
Two significant features of HIV/SIV neuropathology are
astrogliosis and overexpression of Nef in astrocytes, especially
in pediatric neuroAIDS cases and to some extent HIV infected
adult brains (Overholser et al., 2003; Saito et al., 1994;
Takahashi et al., 1996; Tornatore et al., 1994; Trillo-Pazos et
al., 2003). Astrocytes are the most abundant cell type in the
brain and are essential for CNS function by providing
neurotrophic, buffering, and structural support as well as
maintaining glutamate homeostasis. These cells are infected invivo; however, infection is non-productive and appears to be
limited to the early multiply spliced viral gene products,
especially Nef (Ranki et al., 1995; Saito et al., 1994). It has
been suggested that Nef expression disrupts astrocyte function
and alters the CNS microenvironment promoting neuroin-
flammation, leukocyte infiltration, and ultimately, neuronal
injury (Koedel et al., 1999; van Marle et al., 2004). For
example, Nef expression in astrocytes has been shown to
induce cell death as well as the production of neuronal
cytotoxins such as IP-10 and the neurotoxicity induced is
entirely dependent on the specific Nef sequence (He et al.,
1997; van Marle et al., 2004).
The ability of different Nef proteins to associate with or
modulate the activities of distinct signaling pathways/proteins
(Barber et al., 2000) may in fact influence the downstream
effects of Nef expression in infected cells. This could certainly
be the case in astrocytes, in which Nef proteins have been
shown to modulate signaling pathways/proteins in astrocytic
cell lines. The Nef protein of HIV-1SF2 modulates MAPK and
JNK activities as well as the sphingomyelinase pathways
induced by TNF-α in human glial cells in vitro, which by
extension may promote astrogliosis in HIV-infected indivi-
duals (Richard et al., 1997; Robichaud and Poulin, 2000).
Expression of HIV-1LAI Nef in a human astrocytic cell line
inhibits ERK activation induced by the growth factor
endothelin-1 that normally stimulates secretion of nerve
growth factor, which is needed for the survival, growth, and
differentiation of neurons in HIV-1 encephalitic patients
(Romero et al., 1998).
SIV/17E-Fr Nef is expressed in primary astrocytes in vitro
and in the brains of infected macaques in vivo (Overholser et al.,
2003). The downstream effects of SIV/17E-Fr Nef expression in
astrocytes await characterization, but because the SIV/17E-Fr
Nef-associated kinase activity is also observed in cultured
primary astrocytes (data not shown), it seems reasonable to
assume that SIV/17E-Fr Nef associates with CK2 in the brain as
well. CK2 activity in CNS cells has been shown to correlate
with cell survival (Aksenova et al., 1991; Hu and Wieloch,
1993). It is conceivable then that SIV/17E-Fr Nef could
manipulate this function of CK2 to control cell death of
astrocytes which, as mentioned earlier, correlates with CNS
disease.
CK2 has also been shown to inhibit Ca2+-activated K+
channels (Bildl et al., 2004). Since HIV-1LAI Nef has been
shown to inhibit K+ channels in glioma cells (Kort and Jalonen,
1998) and the activity of a Ca2+-activated K+ channels in
CEMx174 cells (Zegarra-Moran et al., 1999), it would not be
surprising if (1) SIV/17E-Fr Nef also inhibits these channels
and/or (2) the ability of HIV-1LAI Nef to inhibit these channels is
mediated by recruitment of CK2. Increased extracellular K+
concentrations can lead to astrocyte swelling and glutamate
release through swelling-activated anion channels (Bednar et
al., 1992) and thus contribute to the neurotoxic environment
associated with HIV/SIV CNS disease (Thompson et al., 2001).
Such speculation requires further experimental analysis without
question, yet underscores the importance of identifying Nef-
associated kinases, not only to elucidate pathogenic
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intervention. In this study, we have shown an association of the
multifunctional Nef protein with the equally multifunctional
CK2, an interaction that could prove useful in further
understanding the role of Nef in neuropathogenesis.
Materials and methods
Cells
293T cells were maintained in DMEM (Gibco) supplemen-
ted with 10% FBS, 10 mM HEPES (Gibco), 2 mM L-glutamine
(Gibco), 2 mM sodium pyruvate (Gibco), and 0.5 mg/mL
gentamicin (Gibco). CEMx174 cells were maintained in RPMI
(Gibco) with 10% FBS, 10 mM HEPES, 2 mM L-glutamine,
and 0.5 mg/mL gentamicin.
Construction of Nef mutants
Nef point mutants were introduced into the infectious
molecular clone SIV/17E-Fr. The construction of SIV/17E-Fr
was described previously (Flaherty et al., 1997). The
construction of SIV/17E-Fr Δnef was previously described
(Flaherty et al., 1997) and contains a mutation of the initiating
methionine and a deletion in the nef gene. Construction of the
point mutation S(12)P in SIV/17E-Fr nef was described
previously (Barber et al., 1998). Mutation of the aspartic acid
at position 15 to alanine or glutamic acid was performed using
site-directed mutagenesis. The subclone pLG-17E-Fr contain-
ing the Nhe1/Bpu1021 fragment from SIV/17E-Fr (Flaherty et
al., 1997) was subjected to PCR using overlapping primers
with a single base mutation. The resulting product was
verified by DNA sequence analysis. The mutated subclone and
SIV/17E-Fr were then cleaved with Nhe1 and Bpu1021. The
Nhe1/Bpu1021 fragment was ligated into the SIV/17E-Fr
backbone using T4 DNA ligase (Gibco). The resulting clones
were verified by DNA sequence analysis.
Transfection protocol
293Tcells were transfected using the LipofectAMINE/PLUS
reagent (Invitrogen). 293T cells were split the day before into
10-cm dishes and were transfected using 37.5 μL LipofectA-
MINE, 75 μL PLUS reagent, and 7.5 μg DNA. Cells are
transfected to high efficiency, as visualized by using a GFP
control transfection. CEMx174 cells were transfected by
electroporation as described previously (Barber et al., 2000).
In vitro kinase reaction using CK2 and Nef
Recombinant CK2 (Promega) and recombinant SIV/17E-Fr
Nef were added to reaction buffer [25mM Tris pH 7.4, 10mM
MgCl2, 200 mM NaCl2, 10 μM cold ATP, and 10 μCi [
32P]-
γATP] for 30 min at 37 °C as recommended (Promega).
Proteins were resolved by SDS-PAGE and analyzed by
phosphorimager. Recombinant SIV/17E-Fr Nef protein was
expressed and purified as a GST-Nef fusion protein (Paragon).The GST-Nef was cleaved by Factor Xa (New England Biolabs)
and the reaction was stopped by addition of 1,5-Dansyl-Glu-
Gly-Arg Chloromethyl Ketone (Calbiochem).
Immunoprecipitation and in vitro kinase assays
293T cells were transfected as described above. The next
day, cells were washed once with PBS containing 0.2 mM
sodium orthovanidate and then lysed Nef lysis buffer containing
0.5% (vol/vol) Nonidet P40, 2 mM EDTA, 137 mM NaCl, 50
mM Tris–HCl (pH 8.0), 10% (vol/vol) glycerol with protease
inhibitors.
Immunoprecipitation was performed with either Nef antise-
rum as described (Barber et al., 2000) or α-CK2 α′ (Promega)
and incubated overnight in a volume of 600 μL lysis buffer at 4
°C after which immunoprecipitates were incubated with Protein
A or G-Sepharose (Sigma) for 1 h at 4 °C. The protein A beads
were washed 3 times with Nef lysis buffer and once with kinase
buffer containing 50 mM Tris–HCl (pH 8.0), 10 mM NaCl, 1%
(vol/vol) Triton X-100, 5 mM MgCl2, 5 mM MnCl2. Protein A
beads were resuspended in 25 μL kinase buffer and 20 μCi
[32P]-γATP or 20 μCi [32P]-γGTP and incubated at 30 °C for
25 min. Reactions were stopped with 1 mL ice-cold lysis buffer
and the products were analyzed by SDS-PAGE.
Experiments using DMAT were performed as described
above except that DMAT, or the appropriate amount of DMSO
(for vehicle control), was added to the kinase buffer. The
reactions were incubated at 30 °C for 15 min before the addition
of ATP for an additional 15 min. All samples, wild type as well
as DMAT- and DMSO-treated, in in vitro kinase assays were
treated exactly the same, with identical incubation times.
Metabolic labeling
293T cells were transfected at high efficiency as described
above. The day after transfection, the cells were labeled either
with [35S]Met/Cys (ICN Radiochemicals Inc.) or [32P]-
orthophosphate (Perkin Elmer). For 35S-labeling, cells were
incubated in methionine-free, cysteine-free DMEM (Invitrogen)
containing 2% FBS, 2 mM L-glutamine, 10 mM HEPES, 2 mM
sodium pyruvate, and 0.5 mg/mL gentamicin for 30 min before
addition of 0.3 mCi/mL [35S]-Met/Cys for 1.5 h. For 32P-
labeling, cells were incubated in phosphate-free DMEM
(Invitrogen) containing 5% dialyzed FBS, 2 mM L-glutamine,
10 mM HEPES, 2 mM sodium pyruvate, and 0.5 mg/mL
gentamicin for 30 min before addition of 0.25 mCi/mL [32P]-
orthophosphate for 1.5 h. In experiments using TBB, the
inhibitor was added at the indicated concentration during the
starvation period and kept in throughout. Cells were harvested
as described above. Proteins were resolved by SDS-PAGE,
visualized, and quantified using a Typhoon 9210
phosphorimager.
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